Subject(s)

Antihypertensive Agents/therapeutic use , Economics, Pharmaceutical , Heart Failure/drug therapy , Mineralocorticoid Receptor Antagonists/therapeutic use , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Spironolactone/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/economics , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/economics , Double-Blind Method , Drug Costs , Heart Failure/economics , Heart Failure/mortality , Humans , Mineralocorticoid Receptor Antagonists/administration & dosage , Mineralocorticoid Receptor Antagonists/economics , Placebos , Prognosis , Ramipril/administration & dosage , Ramipril/economics , Ramipril/therapeutic use , Spironolactone/administration & dosage , Spironolactone/economics , Time Factors